Immunosuppressive drugs in cutaneous lupus erythematosus

Cutaneous Lupus Erythematosus

Volumn , Issue , 2005, Pages 403-418

  Sticherling, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645457416     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-26581-3_29     Document Type: Chapter

References (134)

1. Abe Y, Seno A, Tada J, Arata J (1994) Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol 130:938-939
2. Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro R (1993) Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 20:731-733
3. Abu-Shakra M, Buskila D (2002) Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference. Isr Med Assoc J 4:71-73
4. Abu-Shakra M. Shoenfeld Y (2001) Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10:152-153
5. Arbisier JL, Moschella SL (1995) Clofazimine. A review of its medical uses and mechanisms of action. J Am Acad Dermatol 32:241-247
6. Asherson RA, Lahita RG (1991) Sex hormone modulation in systemic lupus erythematosus. Still a therapeutic option? Ann Rheum Dis 50:897-898
7. Ashinoff R, Werth VP, Frank AG Jr (1988) Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 19:961-965
8. Ayers S Jr, Mihan R (1974) Lupus erythematosus and vitamin E: an effective and non-toxic therapy. Cutis 23:49-52
9. Bergman J, Rico MJ (2001) Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg 20:250-259
10. Boehm I, Bieber T (2001) Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 137:235-236
11. Boehm IB, Boehm GA, Bauer R (1998) Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 18:59-62
12. Bohm L, Uerlich M, Bauer R (1997) Rapid improvement of subacute lupus erythematosus with low-dose methotrexate. Dermatology 194:307-308
13. Bottomley WW, Goodfield MJ (1995a) Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol 133:655-656
14. Bottomley WW, Goodfield MJ (1995b) Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 133:311-314
15. Burkhardt H, Kalden JR (1997) Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol Int 17:85-90
16. Callen JP (2002) Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 16:245-264
17. Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine: an effective, corticosteroidsparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127:515-522
18. Carmichael AJ, Paul CJ (1991) Discoid lupus erythematosus responsive to sulphasalazine. Br J Dermatol 125:291-294
19. Cohen Y, Nagler A (2002) Treatment of refractory autoimmune diseases with lymphoablation and hematopoietic stem cell support. Isr Med Assoc J 4:865-867
20. Conti F, Priori R, Alessandri C, Spinelli FR, Medda E, Valesini G (2000) Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated longterm with cyclosporine A. Lupus 9:676-680
21. Cronstein BN (1996) Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 39:1951-1960
22. Dalziel K, Going G, Cartwright PH, Marks R, Beveridge GW, Rowell NR (1986) Treatment of chronic discoid lupus erythematosus with an oral gold component (auranofin). Br J Dermatol 115:211-216
23. De Vita S, Ferraccioli GF, Di Poi E, Bartoli E, Bombardieri S (1996) High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 14:S85-92
24. DeBandt M, Descamps V, Meyer O (2001) Etanercept-induced systemic lupus erythematosus: two cases on patients with rheumatoid arthritis. Lupus 10:S118
25. Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre M-S, Broly F, Piette F, Bergoend H (1997) Traitement du lupus erythemateux chronique par la sulfasalazine: 11 observations. Ann Dermatol Venereol 124:151-156
26. Dequet CR, Wallace DJ (2001) Novel therapies in the treatment of systemic lupus erythematosus. Curr Opin Investig Drugs 2:1045-1053
27. Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56:690-692
28. Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 21:99-115
29. Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology. An update. Dermatol Clin 16:235-251
30. Englert HJ, Hughes G V R (1988) Danazol and discoid lupus. Br J Dermatol 119:407-409
31. Ferda A (1996) Efficacy of sulfasalazine in discoid lupus erythematosus. Int J Dermatol 10:746-748
32. Furst DE (1999) Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford) 38:14-18
33. Furst DE (2002) Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 14:220-224
34. Furukawa F, Imamura S, Takigawa M (1995) FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Arch Dermatol Res 287:558-563
35. Garcia-Porrua C, Gonzales Gay MA, Fernandez-Lamelo F, Paz-Carreira JM, Lavilla E, Gonzales-Lopez MA (1998) Simultaneous development of SLE-like syndrome and autoimmune thyroiditis following alpha-interferon treatment. Clin Exp Rheumatol 16:107-108
36. Gasparro FP (2000) Photodermatology: progress, problems and prospects. Eur J Dermatol 10:250-254
37. Gelfand EW (2001) Antibody-directed therapy: Past, present and future. J Allergy Clin Immunol 108:111-116
38. Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124-1125
39. Gescuk BD, Davis JC Jr (2002) Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 14:515-521
40. Glant TT, Mikecz K, Brennan F, Negroiu G, Bartlett R (1998) Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. J Rheumatol 25:20-26
41. Goldberg JW, Lidsky MD (1984) Pulse methylprednisolone therapy for persistent subacute cutaneous lupus. Arthritis Rheum 27:837-838
42. Goldstein E, Carey W (1994) Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol 130:938-939
43. Goyal S, Noussari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142-144
44. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS (1991) Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Reumatol 18:1621-1622
45. Gratwohl A, Passweg J, Gerber I, Tyndall A (2001) International Stem Cell Project for Autoimmune Diseases. Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol 14:755-776
46. Griffiths B, Emery P (2001) The treatment of lupus with cyclosporine A. Lupus 10:165-170
47. Hanjani NM, Noussari CH (2002) Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 138:1616-1618
48. Hazelton RA, McCruden AB, Sturrock RD, Stimson WH (1983) Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone. Ann Rheum Dis 42:155-157
49. Isaacs JD (2001) From bench to bedside: discovering rules for antibody design, and improving serotherapy with monclonal antibodies. Rheumatol 40:724-738
50. Isenberg D, Leckie MJ (2002) Biological treatments for systemic lupus erythematosus. Scand J Rheumatol 31:187-191
51. Jansen GT, Dillaha CJ, Honeycutt WM (2001) Discoid lupus erythematosus. Is systemic treatment necessary? Arch Dermatol 92:283-285
52. Jayne D (1999) Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 8:563-567
53. Jeffes EW 3rd, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G (1995) Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth - inhibitory effects of methotrexate. J Invest Dermatol 104:183-188
54. Jessop S, Whitelaw D, Jordaan F (2001) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev CD002954
55. Jolles S, Hughes J, Whittaker S (1998) Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 134:80-86
56. Jungers P, Kuttenn F, Liote F, Pelissier C, Athea N, Laurent MC, Viriot J, Dougados M, Bach JF (1985) Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate. Arthritis Rheum 28:1243-1250
57. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GR (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41:876-882
58. Kilian K, Banyai A, Karadi A, Miklos K, Patranyi GG, Paloczi K (1998) FK-506 (tacrolimus) therapy for an unusual SLE-like disease. Transplant Proc 30:4130-4131
59. Knobler RM, Graninger W, Lindmaier A, Trautinger F, Smolen JS (1992) Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthrit Rheum 32:319-324
60. Krivanek J F C, Paver W K A (1980) Further studies on the use of clofazimine in discoid lupus erythematosus. Australas J Dermatol 21:169-171
61. Kuhn A, Specker C, Ruzicka T, Lehmann P (2002) Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 46:600-603
62. Kurtz ES, Bayley SC, Arshad F, Lee AA, Przekop PA (1995) Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease. Inflamm Res 44:187-188
63. Lernia VD, Bisighini G (1996) Discoid lupus erythematosus during treatment with cyclosporine. Acta Derm Venereol 76:87-88
64. Luger T (2001) Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 11:343-347
65. Machlod KP, Smolen JS (1990) Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 17:831-832
66. Martinez J, de Misa RF, Torrelo A, Ledo A (1992) Low-dose intralesional interferon alfa for discoid lupus erythematosus. J Am Acad Dermatol 26:494-496
67. Martinez J, de Misa RF, Boixeda P, Arrazola JM, Ledo A (1993) Long-term results of intralesional interferon alpha-2B in discoid lupus erythematosus. J Dermatol 20:444-446
68. Masse R, Youinou P, Dorval JC, Cledes J (1980) Reversal of lupus-erythematosus-like disease with danazol. Lancet 20:651
69. McCauliffe DP (2001) Cutaneous lupus erythematosus. Semin Cutan Med Surg 20:14-26
70. McGrath HJ (1994) Ultraviolet A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 12:129-135
71. McGrath H Jr (1997) Prospects for UV-A1 therapy as a treatment modality in cutaneous and systemic LE: Lupus 6:209-217
72. McGrath HJ (1999) Ultraviolet A1 (340-400 nm) irradiation and systemic lupus erythematosus. J Invest Dermatol 4:79-84
73. McGrath HJ, Bak E, Michalski JP (1987) Ultraviolet-A light prolongs survival and improves immune function (New Zealand black x New Zealand white) F1 hybrid mice. Arthritis Rheum 30:557-5611
74. McGrath HJ, Martinez-Osuna P, Lee FA (1996) Ultraviolet A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 5:269-274
75. Millard TP, Hawk J L M (2001) Ultraviolet therapy in lupus. Lupus 10:185-187
76. Molina N, McGrath H Jr. Longterm ultraviolet A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol 24:1072-1074
77. Moore J, Tyndall A, Brooks P (2001) Stem cells in the aetiopathogenesis and therapy of rheumatic disease. Best Pract Res Clin Rheumatol 15:711-726
78. Morley KD, Parke A, Hughes G R V (1982) Systemic lupus erythematosus: two patients treated with danazol. Br Med J 284:1431-1432
79. Morris LF, Lemak NA, Arnett FC Jr, Jordon RE, Duvic M (1996) Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J 89:810-814
80. Nicolas JF, Thivolet J (1989) Interferon alpha therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 321:1550-1551
81. Nicolas JF, Thivolet J, Kanitakis J, Lyonnet S (1990) Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a. J Invest Dermatol 95:142S-145S
82. Nousari HC, Kimyai-Asadi A, Tausk FA (1998) Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 352:1925-1825
83. Obermoser G, Weber F, Sepp N (2001) Discoid lupus erythematosus in a patient receiving cyclosporin for liver transplantation. Acta Derm Venereol 81:319
84. Openshaw H, Nash RA, McSweeney PA (2002) High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol Blood Marrow Transplant 8:233-248
85. Parnham MJ (1995) Leflunomide: a potential new disease modifying anti-rheumatic drug. Exp Opin Invest Drugs 4:777-779
86. Patel PP, Werth V (2002) Cutaneous lupus erythematosus: a review. Dermatol Clin 20:373-385
87. Piette JC (1995) High-dose immunoglobulins in the treatment of refractory cutaneous lupus erythematosus. Open trial in 5 cases. Arthritis Rheum 38:S304
88. Piette JC, Du LT, Papo T (1995) Postmenopausal hormone therapy and systemic lupus erythematosus. Ann Intern Med 122:961-962
89. Pisetksky DS (2000) Tumor necrosis a blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 43:2381-2382
90. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G (1996) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 34:244-252
91. Reid C (2000) Drug treatment of cutaneous lupus. Am J Clin Dermatol 1:375-379
92. Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480-483
93. Richter HI, Krutmann J, Goerz G (1998) Extrakorporale Photopherese bei therapie-refraktärem disseminiertem diskoiden Lupus erythematodes. Hautarzt 49:487-491
94. Robert C, Kupper TS (1999) Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 341:1817-1828
95. Rodriquez-Castellanos MA, Rubio JB, Gomez J F B, Mendoza AG (1995) Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol 131:620-621
96. Ronnblom LE, Alm GV, Oberg KE (1991a) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178-183
97. Ronnblom LE, Alm GV, Oberg KE (1991b) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30:537-540
98. Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG (1988) The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 31:612-615
99. Rudnicka L, Szymanska E, Walecka I, Slowinska M (2000) Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. Dermatology 200:129-131
100. Russell-Jones R (2000) Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 142:16-21
101. Rutter A, Luger T (2001) High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 44:1010-1024
102. Sacher RA (2001) Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108:139-146
103. Saeki Y, Oshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosprin A. Lupus 9:390-392
104. Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174-178
105. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68:1536-1537
106. Schulz EJ, Menter MA (1971) Treatment of discoid and subacute cutaneous lupus erythematosus with cyclophosphamide. Br J Dermatol 85:60-65
107. Singer NG, McCune WJ (1998) Update on immunosuppressive therapy. Curr Opin Rheumatol 10:169-173
108. Solsky M, Wallace DJ (2002) New therapies in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16:293-312
109. Sonnichsen N, Meffert H, Kunzelmann V, Audring H (1993) UV-A-1 therapy of subacute cutaneous lupus erythematosus. Hautarzt 44:723-725
110. Steinkjer B (1995) Auranofin in the treatment of discoid lupus erythematosus. J Dermatol Treat 2:27-29
111. Sticherling M (2001) Chronic cutaneous lupus erythematosus. In: Hertl M (ed) Autoimmune disease of the skin - pathogenesis, diagnosis, management. Springer, Vienna Berlin Heidelberg New York, pp 337-364
112. Sturgess AD, Evans DT, Mackay IR, Riglar A (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11-14
113. Tan BB, Lear TJ, Gawkrodger DJ, English JS (1997) Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 136:351-355
114. Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B (1990) Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol 122:405-409
115. Thoma-Uszynski S, Hertl M (2001) Novel therapeutic approaches in autoimmune skin disorders. In: Hertl M (ed) Autoimmune disease of the skin - pathogenesis, diagnosis, management. Springer, Vienna Berlin Heidelberg New York, pp 337-364
116. Torrelo A, Espana A, Medina S, Ledo A (1990) Danazol and discoid lupus erythematosus. Dermatologica 181:239
117. Tran Q H D, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329-335
118. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, Brush M, Burt RK (2002) Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 46:2917-2923
119. Tsokos GC, Caughman SW, Klippel JH (1985) Successful treatment of generalized discoid lesions with azathioprine. Its use in a patient s with systemic lupus erythematosus. Arch Dermatol 121:1323-1325
120. Tyndall A, Koike T (2002) High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction. Intern Med 41:608-612
121. Tyndall A, Passweg J, Grathwohl A (2000) Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases. Ann Rheum Dis 60:702-707
122. Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147:405-406
123. Wallace D (2001) Current and emerging lupus treatments. Am J Manag Care 7:S490-495
124. Wallace DJ (2002) Management of lupus erythematosus: recent insights. Curr Opin Rheumatol 14:212-219
125. Warner LM, Cummons T, Nolan L, Sehgal SN (1995) Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse. Inflamm Res 44:S205-206
126. Watts RA (2000) Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 12:49-54
127. Werth V (2001) Current treatment of cutaneous lupus erythematosus. Dermatol Online J 7:2-12
128. Werth VP (1993) Management and treatment with systemic glucocorticoids. Adv Dermatol 8:81-101
129. Wilder RL (1998) Hormones, pregnancy, and autoimmune diseases. Ann NY Acad Sci. 840:45-50
130. Wilke WS, Krall PL, Scheetz RJ, Babiak T, Danao T, Mazanec DJ, Segal AM, Clough JD (1991) Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 9:581-587
131. Wollina U, Looks A (1999) Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 13:127-130
132. Yell JA, Burge SM (1994) Cyclosporine and discoid lupus erythematosus. Br J Dermatol 131:132-133
133. Yocum DE (1996) Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 22:133-154
134. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F (2002) Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12:50-52